Methods and compositions for detecting non-hematopoietic cells from a blood sample

Abstract

The present invention recognizes that diagnosis and prognosis of many conditions can depend on the enrichment of rare cells, especially tumor cells, from a complex fluid sample such as a blood sample. In particular, the present invention is directed to methods and compositions for detecting a non-hematopoietic cell, e.g., a non-hematopoietic tumor cell, in a blood sample via, inter alia, removing red blood cells (RBCs) from a blood sample using a non-centrifugation procedure, removing white blood cells (WBCs) from said blood sample to enrich a non-hematopoietic cell, if any, from said blood sample; and assessing the presence, absence and/or amount of said enriched non-hematopoietic cell.

1 . A method for detecting a non-hematopoietic cell in a blood sample, which method comprises:
 a) providing a blood sample;   b) removing red blood cells (RBCs) from said blood sample, with the proviso that said RBCs are not removed from said blood sample via a Ficoll gradient centrifugation, and removing white blood cells (WBCs) from said blood sample to enrich a non-hematopoietic cell, if any, from said blood sample; and   c) assessing the presence, absence and/or amount of said enriched non-hematopoietic cell.   
     
     
         2 . The method of  claim 1 , wherein the blood sample is a whole blood sample or a peripheral blood sample. 
     
     
         3 . The method of  claim 1 , wherein the non-hematopoietic cell to be detected is a non-hematopoietic tumor cell. 
     
     
         4 . The method of  claim 3 , wherein the non-hematopoietic tumor cell is a cancerous cell or a cancer cell. 
     
     
         5 . The method of  claim 1 , wherein the RBCs are removed by sedimentation, filtration, selective lysis, or binding to a specific binding member that specifically binds RBCs. 
     
     
         6 . The method of  claim 5 , wherein the RBC sedimentation is promoted by specifically binding RBCs to a specific binding member that specifically binds RBCs to induce aggregation of the RBCs. 
     
     
         7 . The method of  claim 5 , wherein the RBCs are removed by filtering the blood sample through a microfabricated filter comprising a tapered pore. 
     
     
         8 . The method of  claim 5 , wherein the RBCs are selectively lysed by a hypotonic solution. 
     
     
         9 . The method of  claim 8 , wherein the hypo tonic solution comprises NH 4 Cl, KHCO 3  and EDTA. 
     
     
         10 . The method of  claim 5 , wherein the specific binding member that specifically binds RBCs is a lectin, a receptor ligand or an antibody. 
     
     
         11 . The method of  claim 1 , wherein the WBCs are removed by binding to a specific binding member that specifically binds WBCs. 
     
     
         12 . The method of  claim 11 , wherein the specific binding member is an antibody that specifically binds to WBCs. 
     
     
         13 . The method of  claim 12 , wherein the antibody specifically binds to a ligand selected from the group consisting of CD3, CD11b, CD14, CD17, CD31, CD45, CD50, CD53, CD63, CD69, CD81, CD84, CD102 and CD166. 
     
     
         14 . The method of  claim 11 , wherein the specific binding member is bound to a solid surface. 
     
     
         15 . The method of  claim 14 , wherein the specific binding member is bound directly or indirectly to a solid surface. 
     
     
         16 . The method of  claim 14 , wherein the solid surface is a magnetic particle. 
     
     
         17 . The method of  claim 1 , wherein the RBCs are removed before the WBCs are removed from the blood sample. 
     
     
         18 . The method of  claim 1 , wherein the WBCs are removed before the RBCs are removed from the blood sample. 
     
     
         19 . The method of  claim 1 , which further comprises removing platelets or soluble proteins from the blood sample. 
     
     
         20 . The method of  claim 19 , wherein the RBCs and the platelets are removed by treating the blood sample with a mixture of antibodies that facilitates the agglutination and precipitation of the RBCs and the platelets. 
     
     
         21 . The method of  claim 1 , which further comprises debulking the blood sample. 
     
     
         22 . The method of  claim 1 , wherein the presence, absence and/or amount of the enriched non-hematopoietic cell is assessed by labeling the enriched non-hematopoietic cell and identifying the labeled non-hematopoietic cell. 
     
     
         23 . The method of  claim 22 , wherein the enriched non-hematopoietic cell is labeled by immunostaining, FISH, In situ PCR, In situ hybridization, or staining by a labeled binding member that specifically binds to the enriched non-hematopoietic cell. 
     
     
         24 . The method of  claim 22 , wherein the labeled non-hematopoietic cell is identified by microscopic analysis, flocytometry or a laser based quantitative microscopy technology. 
     
     
         25 . The method of  claim 1 , wherein the presence, absence and/or amount of the enriched non-hematopoietic cell is assessed by PCR. 
     
     
         26 . The method of  claim 25 , wherein the PCR is singleplexed or multiplexed RT-PCR. 
     
     
         27 . The method of  claim 25 , wherein the PCR is qRT-PCR or Real Time PCR. 
     
     
         28 . The method of  claim 1 , wherein the presence, absence and/or amount of the enriched non-hematopoietic cell is assessed by assessing a non-hematopoietic marker in the enriched non-hematopoietic cell. 
     
     
         29 . The method of  claim 28 , wherein the non-hematopoietic marker is an epithelial cell marker in the enriched non-hematopoietic cell. 
     
     
         30 . The method of  claim 29 , wherein a plurality of the epithelial cell markers are assessed. 
     
     
         31 . The method of  claim 29 , which further comprises assessing a tumor specific marker in the enriched non-hematopoietic cell. 
     
     
         32 . The method of  claim 31 , wherein a plurality of the epithelial cell markers and/or the tumor specific markers are assessed. 
     
     
         33 . The method of  claim 1 , which comprises subjecting the enriched, labeled and/or non-hematopoietic cell to additional analysis. 
     
     
         34 . The method of  claim 33 , wherein the additional analysis is selected from the group consisting of PCR, oligonucleotide ligation assay (OLA), laser dissection microscopy (LDM), whole genome amplification (WGA), comparative genomic hybridization (CGH), DNA methylation assay, microarray analysis or a combination thereof. 
     
     
         35 . The method of  claim 33 , wherein the additional analysis comprises assessing DNA methylation of the enriched non-hematopoietic cell. 
     
     
         36 . The method of  claim 27 , wherein the non-hematopoietic marker is a protein or mRNA specifically expressed in epithelial and/or endothelial cells, DNA methylation pattern of the enriched non-hematopoietic cell or the chromosomal ploidy of the enriched non-hematopoietic cell. 
     
     
         37 . The method of  claim 3 , wherein the tumor is a solid tumor. 
     
     
         38 . The method of  claim 37 , wherein the solid tumor is selected from the group consisting of tumor of breast, colon, prostate, ovary, lung, liver, pancreatic, gastric, skin, melanoma, glioma, pharyngeal, esophagus, cervical and bladder. 
     
     
         39 . The method of  claim 1 , which further comprises enriching the initially enriched non-hematopoietic cell. 
     
     
         40 . The method of  claim 39 , wherein the initially enriched non-hematopoietic cell is further enriched by a positive selection of the non-hematopoietic cell or flowcytometry sorter. 
     
     
         41 . The method of  claim 22 , which further comprises comparing the amount or number of the labeled and identified non-hematopoietic cell obtained in the test sample to the amount or number of the labeled and identified non-hematopoietic cell obtained in a comparable control sample. 
     
     
         42 . The method of  claim 25 , which further comprises comparing the amount of a mRNA in the non-hematopoietic cell of the test sample to the amount of the mRNA in a non-hematopoietic cell obtained in a comparable control sample. 
     
     
         43 . A method for detecting a non-hematopoietic cell in a blood sample, which method comprises:
 a) providing a blood sample;   b) removing red blood cells (RBCs) from said blood sample by selectively lysing said RBCs, and removing white blood cells (WBCs) by specific binding of said WBCs to an anti-CD50 antibody from said blood sample to enrich a non-hematopoietic cell, if any, from said blood sample; and   c) assessing the presence, absence and/or amount of said enriched non-hematopoietic cell by:
 i) immunostaining the enriched non-hematopoietic cell and counting the labeled cell; 
 ii) or PCR analysis of the enriched non-hematopoietic cell. 
   
     
     
         44 . The method of  claim 43 , wherein the non-hematopoietic cell is a non-hematopoietic tumor cell. 
     
     
         45 . A kit for detecting a non-hematopoietic cell in a blood sample, which kit comprises:
 a) means for removing red blood cells (RBCs) from a blood sample, with the proviso that said means is not a Ficoll gradient centrifugation means, and means for removing white blood cells (WBCs) from said blood sample to enrich a non-hematopoietic cell, if any, from said blood sample; and   b) means for assessing the presence, absence and/or amount of said enriched non-hematopoietic cell.   
     
     
         46 . The kit of  claim 45 , wherein the non-hematopoietic cell is a non-hematopoietic tumor cell.